This clinical trial is for men (18 years or older) with metastatic castration-resistant prostate cancer (mCRPC).
   
The purpose of this study is to identify a dose of JANX007 that is well tolerated. 
   
JANX007 is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).
   

This expanded access study is for men and women whose immune cells (T cells) were genetically engineered to create a treatment called brexucabtagene autoleucel, but the genetically engineered cells did not meet the U.S. Food and Drug Administration’s (FDA) approved criteria for release back to the participant for treatment. If the participant’s doctor feels that treatment with the commercially out-of-specification brexucabtagene autoleucel is still the best option, the participant can receive the out-of-specification product through this program.
   

The purpose of this research study is to evaluate the effect of Efruxifermin compared to placebo on achieving nonalcoholic steatohepatitis (NASH) resolution and fibrosis regression in participants with fibrosis stage 2 or 3.

 The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

SGR-1505 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA). 
   
In this study, SGR-1505 will be taken orally either once daily or every 12 hours.

The purpose of this clinical research study is to see whether 2 investigational study drugs, Guselkumab and Mirikizumab, work in patients with Crohn’s disease (CD) who are 2 to 17 years of age at the time of joining the study.

Investigational means that these drugs are not approved by the U.S. Food and Drug Administration (FDA). 

This research study is for men and women who have been diagnosed with hematological or solid tumor indications or advanced malignancies and who participated previously in studies (a parent study) involving pelabresib, an experimental anti-cancer drug.

The purpose of this study is to compare the efficacy of the Pain Identification and Communication Toolkit (PICT) with a Health Promotion (HP) program.

Participants will be assigned to either the Pain Identification and Communication Toolkit (PICT/intervention) or Health Promotion (HP/attention control) group. There is an equal chance of being placed into either of the study groups, like flipping a coin.

The main purpose of this study with the corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study. The purpose of this research study is to see if Selinexor is an effective treatment for MF.

This is a multi-center Phase 1/2 clinical trial to evaluate the safety, prostate-specific antigen (PSA) response, and immunogenicity of the VTP850 prime-boost immunotherapeutic in men with biochemical recurrence of prostate cancer after definitive local therapy. 
   
VTP-850 is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration.

The purpose of this study is to determine if endothelial cells derived from the human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.